Friday 6 November 2026 Export EXEL’s income statement to Excel — free account

Exelixis, Inc.

EXEL Healthcare Biotechnology

Exelixis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 6.98% from fiscal 2024.

Revenue: +10.2%
EPS: +22.8%
Free cash flow: −4.83%

Quarter to September 2026, against a year earlier

Revenue growth 10 yrs

69.55 0.84 +1.22%

Follow EXEL

Alert me

Market cap: $16.8B
P/E: 20.1×
Fwd P/E: 20.2×
Dividend yield: —
F-score: 7/9
Altman Z: 12.68
Beneish M: −2.61
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Exelixis, Inc. 10-K filed Feb 10, 2026

Fiscal year 2025 · Period ended Jan 2, 2026 · Filed Feb 10, 2026 · accepted 4:32 PM ET · Document on sec.gov · Filing index

What changed

Item 1, Business Item 1A, Risk Factors Item 7, Management’s Discussion and Analysis

Item 1A, Risk Factors, against the 10-K filed Feb 11, 2025: 12 added · 3 removed · 68 modified